New Purification Process for Adenoviral Vectors
By Biotechdaily staff writers
Posted on 17 Jan 2003
A new process has been developed that is designed to significantly improve the purification of adenoviral vectors and thereby reduce undesired toxic and immune response side effects of gene therapies and vaccines. The method was reported in the November 1, 2002, issue of Human Gene Therapy.Posted on 17 Jan 2003
Called AdenoServe, the new method incorporates improvements in adenovirus propagation as well as a tandem chromatography purification process that employs the PolyFlo resin of Puresyn, Inc. (Malvern, PA, USA; www.puresyn.com). The process was developed by scientists at Puresyn and the University of Pennsylvania's Institute for Human Gene Therapy (Philadelphia, USA).
The process virtually eliminates host cell and free viral proteins, says Puresyn. The yield of infectious viral particles is usually more than 50%, twice the amount obtained with the current standard double cesium chloride gradient technique. Viral particle to infectious unit ratios of less than 30 are typical, resulting in more potent adenovirus preparations.
The scalable process is now available from Puresyn as a new contract adenovirus production service.
Related Links:
Puresyn
Univ. of Penn.
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
